| Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC (NCT06081673) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2023-10-30 |
| Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients (NCT06014801) | Jikei University School of Medicine | 2023-10-30 |
| Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib (NCT06114407) | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 2023-10-30 |
| The Efficacy of Using Pentoxifylline in Patients Undergoing Breast Cancer Surgery (NCT06087237) | Mansoura University | 2023-10-30 |
| Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma (NCT06092645) | Zhejiang Cancer Hospital | 2023-10-30 |
| Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma (NCT06190067) | Navy General Hospital, Beijing | 2023-10-30 |
| Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma (NCT06140732) | Xuanwu Hospital, Beijing | 2023-10-30 |
| Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging) (NCT07265596) | Michael J. Fox Foundation for Parkinson's Research | 2023-10-30 |
| A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (NCT06013241) | Insmed Incorporated | 2023-10-30 |
| Complete Digital Workflow (NCT07091786) | Mansoura University | 2023-10-30 |
| Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC (NCT06125041) | Qianfoshan Hospital | 2023-10-30 |
| Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL (NCT06062641) | Ruijin Hospital | 2023-10-30 |
| Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment (NCT06081595) | Jin Li | 2023-10-30 |
| Azelastine Allergen Chamber - Onset of Action Study (NCT06126952) | MEDA Pharma GmbH & Co. KG | 2023-10-30 |
| IN10018 Combination Therapy in Treatment-naïve ES-SCLC (NCT06030258) | InxMed (Shanghai) Co., Ltd. | 2023-10-30 |
| Study of ALE.C04 in Patients With Head and Neck Cancer (NCT06054477) | Alentis Therapeutics AG | 2023-10-30 |
| A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive (NCT05879822) | Incyte Corporation | 2023-10-30 |
| The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study (NCT06125080) | Huihua Xiong | 2023-10-30 |
| PK and PD Study of NPI-001 and Cysteamine Bitartrate (NCT05994534) | Nacuity Pharmaceuticals, Inc. | 2023-10-29 |
| XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM) (NCT06147505) | Dushu Lake Hospital Affiliated to Soochow University | 2023-10-29 |
| Janus Kinase Inhibition in Granuloma Annulare (NCT05650736) | William Damsky | 2023-10-27 |
| Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (NCT05978284) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2023-10-27 |
| Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® (NCT06319235) | MB PHARMA s.r.o. | 2023-10-27 |
| Realizing Effectiveness Across Continents With Hydroxyurea (NCT06171217) | Children's Hospital Medical Center, Cincinnati | 2023-10-27 |
| A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. (NCT06008288) | Allist Pharmaceuticals, Inc. | 2023-10-27 |
| Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma (NCT06254911) | Emory University | 2023-10-27 |
| Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (NCT05980000) | Washington University School of Medicine | 2023-10-27 |
| Efficacy of Probiotic Against Functional Constipation (NCT06122558) | Min-Tze LIONG | 2023-10-27 |
| Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS (NCT06109064) | Anhui Provincial Hospital | 2023-10-27 |
| KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer (NCT05985109) | Peking University Cancer Hospital & Institute | 2023-10-26 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) (NCT05892614) | aTyr Pharma, Inc. | 2023-10-26 |
| OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM (NCT06182696) | OriCell Therapeutics Co., Ltd. | 2023-10-26 |
| A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours (NCT06725758) | Orion Corporation, Orion Pharma | 2023-10-26 |
| Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection (NCT05655091) | University Hospital, Basel, Switzerland | 2023-10-26 |
| A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis (NCT06073119) | Sanofi | 2023-10-26 |
| Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy (NCT05962450) | Beijing YouAn Hospital | 2023-10-26 |
| Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) (NCT05710666) | Cancer Trials Ireland | 2023-10-26 |
| Durvalumab and Tremelimumab in Resectable HCC (NCT05440864) | University Health Network, Toronto | 2023-10-26 |
| Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (NCT05900206) | Karolinska University Hospital | 2023-10-26 |
| Intensive Speech Motor Chaining Treatment for Residual Speech Sound Disorders (NCT05929859) | Syracuse University | 2023-10-26 |
| XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study (NCT06091423) | Xiaofeng Chen | 2023-10-25 |
| The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) (NCT06112041) | Second Affiliated Hospital of Soochow University | 2023-10-25 |
| DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (NCT05770102) | Cancer Research UK | 2023-10-25 |
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) (NCT06108219) | Corcept Therapeutics | 2023-10-25 |
| Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease (NCT06114329) | AceLink Therapeutics, Inc. | 2023-10-25 |
| Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (NCT06144424) | Escient Pharmaceuticals, Inc | 2023-10-25 |
| Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects (NCT05715619) | Intralytix, Inc. | 2023-10-25 |
| A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC (NCT06190639) | Zhejiang Cancer Hospital | 2023-10-25 |
| Nectero EAST System Clinical Study (NCT06001918) | Nectero Medical, Inc. | 2023-10-25 |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors (NCT06060613) | Obsidian Therapeutics, Inc. | 2023-10-25 |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma (NCT05836571) | National Cancer Institute LAO | 2023-10-25 |
| Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program (NCT05878119) | Metro International Biotech, LLC | 2023-10-25 |
| Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC (NCT06904014) | Lei ZHAO | 2023-10-25 |
| Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB) (NCT06229665) | LumiThera, Inc. | 2023-10-25 |
| KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade (NCT06099821) | Peking University Cancer Hospital & Institute | 2023-10-25 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers (NCT06119685) | Indapta Therapeutics, INC. | 2023-10-25 |
| Valacyclovir in Pain Management of Acute Apical Abscesses (NCT05266040) | University of California, San Francisco | 2023-10-25 |
| T-DM1 Combined With CDK4/6 Inhibitor Ribociclib (NCT06481956) | Zheng Yabing | 2023-10-25 |
| Stellate Ganglion Block for COVID-induced Parosmia (NCT06253806) | Washington University School of Medicine | 2023-10-25 |
| Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis (NCT06101823) | Opsidio, LLC | 2023-10-25 |
| Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (NCT06077656) | Inventprise Inc. | 2023-10-25 |
| Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients (NCT06126380) | Eledon Pharmaceuticals | 2023-10-25 |
| Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults (NCT06039579) | ViiV Healthcare | 2023-10-25 |
| Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients (NCT06176729) | Yan Zhang, MD | 2023-10-24 |
| Shingrix In Recipients of Allogeneic Transplants (NCT05775718) | University of Colorado, Denver | 2023-10-24 |
| A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer (NCT05759728) | Carina Biotech Limited | 2023-10-24 |
| The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (NCT05938712) | University Health Network, Toronto | 2023-10-24 |
| A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases (NCT05755035) | Takeda | 2023-10-24 |
| Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (NCT07034053) | Ekaterina Laukhtina | 2023-10-24 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors (NCT06077877) | GlaxoSmithKline | 2023-10-24 |
| Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation (NCT05967052) | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 2023-10-24 |
| A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus (NCT06097299) | ModernaTX, Inc. | 2023-10-24 |
| Down Syndrome Obstructive Sleep Apnea (NCT06043440) | Brigham and Women's Hospital | 2023-10-24 |
| High-Dose Ambroxol in GBA1-Related Parkinson (NCT06193421) | Agyany Pharma LTD | 2023-10-24 |
| To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) (NCT05968768) | Anna Raciborska | 2023-10-24 |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents (NCT06090266) | OncoResponse, Inc. | 2023-10-24 |
| Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer (NCT05980689) | Sun Yat-sen University | 2023-10-24 |
| Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial (NCT05967286) | National Cancer Institute (NCI) | 2023-10-23 |
| Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT06165380) | Li Zhang | 2023-10-23 |
| Assessing Physical Function in Sickle Cell Patients Taking Voxelotor (NCT06023199) | Inova Health Care Services | 2023-10-23 |
| Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome (NCT05482334) | University of Colorado, Denver | 2023-10-23 |
| Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer (NCT05947383) | Sunstone Medical | 2023-10-23 |
| Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma (NCT05921760) | Servier Bio-Innovation LLC | 2023-10-23 |
| Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) (NCT05988372) | Sun Yat-sen University | 2023-10-23 |
| A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (NCT06046729) | Eli Lilly and Company | 2023-10-23 |
| A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia (NCT05952037) | BeOne Medicines | 2023-10-23 |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (NCT05972135) | SCRI Development Innovations, LLC | 2023-10-23 |
| A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (NCT06029127) | BeiGene | 2023-10-23 |
| Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail (NCT06108596) | The First Affiliated Hospital with Nanjing Medical University | 2023-10-21 |
| Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine (NCT05994703) | Rose Research Center, LLC | 2023-10-20 |
| Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease (NCT06079190) | GlaxoSmithKline | 2023-10-20 |
| A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (NCT06006169) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-10-20 |
| Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia (NCT06982274) | Instituto do Cancer do Estado de São Paulo | 2023-10-20 |
| Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma (NCT06140966) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2023-10-20 |
| Home-based Transcranial Direct Current Stimulation (tDCS) to Promote Social Communication and Behaviour in Children With Autism Spectrum Disorder (ASD) (NCT06129058) | Holland Bloorview Kids Rehabilitation Hospital | 2023-10-20 |
| Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC (NCT05993858) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2023-10-20 |
| Melatonin Use in Patients With Climacterious Symptoms in the Perimenopause (NCT06192641) | Univates | 2023-10-20 |
| Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure (NCT05598333) | AskBio Inc | 2023-10-20 |
| A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39) (NCT06041802) | Merck Sharp & Dohme LLC | 2023-10-20 |
| A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration (NCT06074783) | Cellcolabs Clinical LTD. | 2023-10-20 |